Indegene posts Q1 net profit higher by 33% YoY to Rs. 116.4 Cr
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
For patients with resectable early-stage gastric and gastroesophageal junction cancers
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
Upgrades 2025 full-year CDMO sales and margin outlook
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Subscribe To Our Newsletter & Stay Updated